title: [Effect of antiasthenic drug ladasten on the level of cytokines and behavior in experimental model of anxious depression in C57BL/6 male mice].
abstract: Effects of the antiasthenic drug ladasten [N-(2-adamantyl)-N-(para-bromophenyl)amine] on the profile of cytokines, behavior, and indexes of immunity organs was studied on zoosocial stress model in depressed C57BL/6 male mice. The anxious depression state in male mice was formed by repeated agonistic interactions according to the sensory contact model. Ladasten (30 mg/kg, i.p.) and reference drug imipramine (10 mg/kg, i.p.) were administered either once after 3-day stressor interaction or for 5 days after 10-day interaction. The concentration of cytokines in blood serum was determined by flow cytometry method. The behavioral changes were studied using an actometer and the elevated plus-maze test. The parameters were studied 24 h after last drug injection. Different stages of depression were manifested by behavioral impairments, increased concentration of pro-inflammatory cytokines IL-6, IL-17, and IL-4, and decreased indexes of immunity organs. Ladasten induced (more significantly than imipramine) a decrease in the level of pro-inflammatory cytokines IL-6, IL-17 and IL-4, removed behavioral changes, and restored indexes of immunity organs. Thus, the antiasthenic drug ladasten limits development of the anxious depressive state and suppresses the level ofproinflammatory cytokines IL-6, IL-17 and IL-4. These findings suggest that ladasten is a possible candidate drug for adjuvant therapy of depressive disorders.
authors.forename: A V
authors.initials: AV
authors.lastname: Tallerova
authors.forename: L P
authors.initials: LP
authors.lastname: Kovalenko
authors.forename: A D
authors.initials: AD
authors.lastname: Durnev
authors.forename: S B
authors.initials: SB
authors.lastname: Seredenin
mesh_terms: D000218:Adamantane / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D001522:Behavior, Animal / Q000187:drug effects*; D003863:Depression / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D004195:Disease Models, Animal; D007099:Imipramine / Q000008:administration & dosage / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D007274:Injections, Intraperitoneal; D020381:Interleukin-17 / Q000096:biosynthesis / Q000276:immunology; D015847:Interleukin-4 / Q000096:biosynthesis / Q000276:immunology; D015850:Interleukin-6 / Q000096:biosynthesis / Q000276:immunology; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D009043:Motor Activity / Q000187:drug effects; D009929:Organ Size; D013154:Spleen / Q000187:drug effects / Q000276:immunology; D013315:Stress, Psychological / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D013950:Thymus Gland / Q000187:drug effects / Q000276:immunology
chemical_list: D000928:Antidepressive Agents; D020381:Interleukin-17; D015850:Interleukin-6; C493151:N-(2-adamantyl)-N-p-bromophenylamine; D015847:Interleukin-4; D007099:Imipramine; D000218:Adamantane